ReviewCancers2020
PLZF-RAR
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Acute promyelocytic leukemia with a unique genetic signature: a case report and management.Discover oncology · 2026Article
- The novel ETV6::RARA fusion gene, identified in acute promyelocytic leukemia, is sensitive to invitro all-tans retinoic acid and arsenic trioxide administrations.Annals of hematology · 2026Article
- Acute Non-promyelocytic Leukemia with Complex Karyotype and Novel t (15;17) (q21; p11.2)/B2M:Cardiovascular & hematological disorders drug targets · 2026Article
- Case Report: Clinical response to TKI therapy in T-cell acute lymphoblastic leukemia with rareFrontiers in oncology · 2026Article
- Palmitoyltransferase ZDHHC3 is essential for the oncogenic activity of PML/RARα in acute promyelocytic leukemia.Acta pharmacologica Sinica · 2025Article
- Review
- Spinal myeloid sarcoma presenting as initial symptom in acute promyelocytic leukemia with a rare crypticFrontiers in oncology · 2024Article
- The Frequency, Clinico-Hematological Features, and Outcome of Acute Promyelocytic Leukemia with VariantIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024Article
- Article
- Association betweenThe Journal of international medical research · 2022Article
- Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA.British journal of haematology · 2022Article
- Noncanonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias.Blood · 2022Article
- Article
- ZBTB16-RARα-Positive Atypical Promyelocytic Leukemia: A Case Report.Medicina (Kaunas, Lithuania) · 2022Article
- Improved Gene Fusion Detection in Childhood Cancer Diagnostics Using RNA Sequencing.JCO precision oncology · 2022Article
- Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis.Frontiers in oncology · 2022Review
- Acute Promyelocytic Leukemia.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 14 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been suggested that 1-2% of acute promyelocytic leukemia (APL) patients present variant rearrangements of retinoic acid receptor alpha (RARα) fusion gene, with the promyelocytic leukaemia zinc finger (PLZF)/RAR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.